Publications by authors named "Jin-Cheng Xiao"
Objective: Though synergy of sorafenib and transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC) is well discussed in previous reports, association of lipiodol retention by sorafenib addition to TACE with the survival outcomes remain elusive. Therefore, we studied the impact of sorafenib addition to TACE on survival outcomes mediated by lipiodol retention.
Materials And Methods: This is a long-term, retrospective, single-center study using medical records of patients diagnosed with HCC at the Department of Interventional Radiology of Zhengzhou University Affiliated Cancer Hospital (China) between April 2004 and March 2012.
Article Synopsis
- The study aimed to evaluate how lactulose affects the immune system of hepatocellular carcinoma patients who also have cirrhosis and hypersplenism after undergoing certain medical treatments.
- A total of 40 patients were divided into two groups; one received lactulose in addition to standard treatment, while the other only received treatment.
- Results showed that those taking lactulose had improved blood cell counts and reduced liver enzyme levels, suggesting that lactulose helps balance the body's oxidation and antioxidant systems in these patients.
This study evaluated the factors impacting overall survival (OS) and time to progression (TTP) in patients with unresectable hepatocellular carcinoma (HCC) who received transarterial chemoembolization (TACE). HCC patients were grouped based on tumor vascularity and lipidiol deposition after TACE. Tumor vascularity was classified based on contrast enhancement on arterial phase baseline CT scans.
View Article and Find Full Text PDFObjective: To observe the therapeutic effects of arsenic trioxide combined with transcatheter arterial chemoembolization on treatment of primary liver cancer with pulmonary metastases.
Methods: Sixty patients were randomly divided into two groups: group A (treatment group, n = 30) and group B (control group, n = 30). Group A was received periodic transcatheter arterial chemoembolization (TACE) and 10 mg arsenic trioxide by intravenous infusion for 5 hours per day, 3 days after TACE.